<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>WeBrovy.com | Evidence-Based GLP-1 Guidance for Men</title>
  <meta name="description" content="Evidence-based guidance for men using GLP-1 medications for weight management. Practical, scientifically grounded resources on training, nutrition, side-effect management, and GLP-1 science.">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Merriweather:wght@400;700&display=swap" rel="stylesheet">
  <link rel="icon" type="image/svg+xml" href="favicon.svg">
  <link rel="stylesheet" href="styles.css">
</head>
<body>

  <!-- Navigation -->
  <nav class="nav" id="nav">
    <div class="nav-container">
      <a href="#" class="nav-logo">
        <svg class="logo-icon" viewBox="0 0 44 44" fill="none" xmlns="http://www.w3.org/2000/svg">
          <rect x="0" y="0" width="44" height="44" rx="10" fill="#1a5276"/>
          <path d="M8 24 L14 24 L17.5 14 L22 34 L26.5 10 L30 24 L36 24" stroke="#1abc9c" stroke-width="2.8" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
          <circle cx="26.5" cy="10" r="2" fill="#1abc9c" opacity="0.4"/>
        </svg>
        <span class="nav-wordmark">We<em>Brovy</em></span>
      </a>
      <button class="nav-toggle" id="navToggle" aria-label="Toggle navigation">
        <span></span><span></span><span></span>
      </button>
      <ul class="nav-links" id="navLinks">
        <li><a href="#start-here">Start Here</a></li>
        <li><a href="#what-are-glp1s">GLP-1 Basics</a></li>
        <li><a href="#medications">Medications</a></li>
        <li><a href="#side-effects">Side Effects</a></li>
        <li><a href="#nutrition">Nutrition</a></li>
        <li><a href="#exercise">Training</a></li>
        <li><a href="#faq">FAQ</a></li>
        <li><a href="#editorial-standards">Standards</a></li>
      </ul>
    </div>
  </nav>

  <!-- Hero Section -->
  <header class="hero">
    <div class="hero-bg"></div>
    <div class="container hero-content">
      <div class="hero-badge">A Guide for Guys Taking GLP-1 for Weight Management</div>
      <h1>Evidence-Based GLP-1 Guidance for Men</h1>
      <p class="hero-subtitle">Practical, scientifically grounded resources on training, nutrition, side-effect management, and GLP-1 science. We're here to help you make informed decisions and have better conversations with your clinician.</p>
      <div class="hero-actions">
        <a href="#start-here" class="btn btn-primary">Start Here</a>
        <a href="#what-you-will-find" class="btn btn-outline">Browse Guides</a>
        <a href="#weekly-digest" class="btn btn-outline">Read the Weekly Digest</a>
      </div>
      <div class="hero-stats">
        <div class="stat">
          <span class="stat-number">6</span>
          <span class="stat-label">FDA-Approved GLP-1 Medications</span>
        </div>
        <div class="stat-divider"></div>
        <div class="stat">
          <span class="stat-number">15-22%</span>
          <span class="stat-label">Average Body Weight Reduction</span>
        </div>
        <div class="stat-divider"></div>
        <div class="stat">
          <span class="stat-number">2005</span>
          <span class="stat-label">First FDA Approval Year</span>
        </div>
      </div>
    </div>
  </header>

  <!-- Trust Bar -->
  <section class="trust-bar">
    <div class="container">
      <div class="trust-items">
        <div class="trust-item">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 12l2 2 4-4"/><path d="M12 2a10 10 0 1 0 0 20 10 10 0 0 0 0-20z"/></svg>
          <span>FDA-Approved Medications Only</span>
        </div>
        <div class="trust-item">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M2 3h6a4 4 0 0 1 4 4v14a3 3 0 0 0-3-3H2z"/><path d="M22 3h-6a4 4 0 0 0-4 4v14a3 3 0 0 1 3-3h7z"/></svg>
          <span>Primary Sources Cited</span>
        </div>
        <div class="trust-item">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M16 21v-2a4 4 0 0 0-4-4H6a4 4 0 0 0-4 4v2"/><circle cx="9" cy="7" r="4"/><path d="M22 21v-2a4 4 0 0 0-3-3.87"/><path d="M16 3.13a4 4 0 0 1 0 7.75"/></svg>
          <span>Built for Men</span>
        </div>
        <div class="trust-item">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"/></svg>
          <span>Independent &middot; Self-Funded</span>
        </div>
        <div class="trust-item">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M22 12h-4l-3 9L9 3l-3 9H2"/></svg>
          <span>Evidence Graded</span>
        </div>
      </div>
    </div>
  </section>

  <!-- Start Here -->
  <section class="section" id="start-here">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Welcome to WeBrovy.com</span>
        <h2>Start Here</h2>
        <p class="section-intro">WeBrovy.com is a practical, evidence-based resource for men using GLP-1 medications&mdash;especially those balancing weight management with training, muscle retention, and long-term health.</p>
      </div>

      <div class="start-here-grid">
        <div class="sh-card">
          <h3>Who This Is For</h3>
          <ul class="check-list">
            <li>Men currently using a GLP-1 (or considering one with a clinician)</li>
            <li>Men who want clear guidance on training, nutrition, and tolerability</li>
            <li>Men who prefer evidence-based information over hype</li>
          </ul>
        </div>
        <div class="sh-card">
          <h3>What You'll Get</h3>
          <ul class="check-list">
            <li><strong>Guides:</strong> structured "field manual" content you can return to</li>
            <li><strong>Weekly Digest:</strong> curated research and news summaries with an evidence grade</li>
            <li><strong>Side-Effect Playbooks:</strong> practical strategies and red flags to know</li>
          </ul>
        </div>
        <div class="sh-card sh-card-not">
          <h3>What This Is Not</h3>
          <ul class="check-list-x">
            <li>A substitute for medical care</li>
            <li>A place for shortcuts, miracle claims, or unverified "biohacks"</li>
            <li>A site that promotes unapproved or questionable products</li>
          </ul>
        </div>
        <div class="sh-card">
          <h3>How to Use This Site</h3>
          <ol class="numbered-list">
            <li>Start with <a href="#what-are-glp1s">GLP-1 Basics for Men</a> below</li>
            <li>Choose your priority: <a href="#exercise">Training</a>, <a href="#nutrition">Nutrition</a>, or <a href="#side-effects">Side Effects</a></li>
            <li>Subscribe to the <a href="#weekly-digest">Weekly Digest</a> to stay current</li>
            <li>Bring questions to your clinician using our conversation prompts</li>
          </ol>
        </div>
      </div>
    </div>
  </section>

  <!-- What You'll Find Here -->
  <section class="section section-alt" id="what-you-will-find">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Your Resources</span>
        <h2>What You'll Find Here</h2>
      </div>

      <div class="find-here-grid">
        <div class="fh-card">
          <div class="fh-icon">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M2 3h6a4 4 0 0 1 4 4v14a3 3 0 0 0-3-3H2z"/><path d="M22 3h-6a4 4 0 0 0-4 4v14a3 3 0 0 1 3-3h7z"/></svg>
          </div>
          <h3>Guides</h3>
          <p>Evergreen playbooks designed for real life, built around the best available evidence and updated as the science changes.</p>
          <div class="fh-topics">
            <span class="fh-topic">Exercise &amp; Muscle Retention</span>
            <span class="fh-topic">Nutrition &amp; Protein</span>
            <span class="fh-topic">GLP-1 Science</span>
            <span class="fh-topic">Partnering with Your Clinician</span>
          </div>
        </div>

        <div class="fh-card">
          <div class="fh-icon">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><rect x="3" y="4" width="18" height="18" rx="2" ry="2"/><line x1="16" y1="2" x2="16" y2="6"/><line x1="8" y1="2" x2="8" y2="6"/><line x1="3" y1="10" x2="21" y2="10"/></svg>
          </div>
          <h3>Weekly Digest</h3>
          <p>A curated summary of GLP-1 developments, with plain-language takeaways and an evidence grade so you can quickly gauge confidence.</p>
          <div class="evidence-grades-mini">
            <span class="eg-mini a">Grade A</span> Guidelines, large RCTs, meta-analyses
            <span class="eg-mini b">Grade B</span> Smaller RCTs, strong observational studies
            <span class="eg-mini c">Grade C</span> Preprints, early findings, provisional
          </div>
        </div>

        <div class="fh-card">
          <div class="fh-icon">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"/></svg>
          </div>
          <h3>Side-Effect Playbooks</h3>
          <p>Practical approaches for common GI effects and adherence challenges, including "what to try first" and "when to talk to a clinician."</p>
          <a href="#side-effects" class="fh-link">View Side-Effect Playbook &rarr;</a>
        </div>
      </div>
    </div>
  </section>

  <!-- Our Approach -->
  <section class="section" id="our-approach">
    <div class="container">
      <div class="section-header">
        <span class="section-label">How We Work</span>
        <h2>Our Approach</h2>
        <p class="section-intro">Health information should be accurate, transparent, and useful. Here's how we hold ourselves to that standard.</p>
      </div>

      <div class="approach-grid">
        <div class="approach-card">
          <div class="approach-number">1</div>
          <h4>Cite Primary Sources</h4>
          <p>We reference clinical guidelines, prescribing information, and peer-reviewed studies whenever possible.</p>
        </div>
        <div class="approach-card">
          <div class="approach-number">2</div>
          <h4>Separate Evidence from Opinion</h4>
          <p>When we share perspective, we label it clearly. Evidence and editorial voice never blur.</p>
        </div>
        <div class="approach-card">
          <div class="approach-number">3</div>
          <h4>Acknowledge Uncertainty</h4>
          <p>When evidence is limited or evolving, we say so explicitly. Science is a process, not a press release.</p>
        </div>
        <div class="approach-card">
          <div class="approach-number">4</div>
          <h4>Update When It Matters</h4>
          <p>We aim to update evergreen guides at least every 6&ndash;12 months, or sooner when major evidence, guidance, or safety information changes.</p>
        </div>
      </div>

      <div class="approach-cta">
        <a href="#editorial-standards" class="btn-text">Read our full Editorial Standards &rarr;</a>
      </div>
    </div>
  </section>

  <!-- What Are GLP-1s -->
  <section class="section" id="what-are-glp1s">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Understanding the Science</span>
        <h2>What Are GLP-1 Receptor Agonists?</h2>
        <p class="section-intro">GLP-1 receptor agonists are a class of medications that mimic the incretin hormone GLP-1 (glucagon-like peptide-1), which your body naturally produces in response to food intake.</p>
      </div>

      <div class="info-grid">
        <div class="info-card featured">
          <div class="info-card-icon">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><circle cx="12" cy="12" r="10"/><path d="M12 6v6l4 2"/></svg>
          </div>
          <h3>How They Work</h3>
          <p>GLP-1 receptor agonists bind to GLP-1 receptors throughout your body, triggering multiple physiological responses. They slow gastric emptying, increase insulin secretion in response to meals, suppress glucagon release, and act on brain regions that regulate appetite and satiety.</p>
          <p>Unlike the natural GLP-1 hormone (which is broken down within minutes), these medications are engineered to resist degradation, allowing them to work for days or even weeks.</p>
        </div>

        <div class="info-card">
          <div class="info-card-icon blue">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M22 12h-4l-3 9L9 3l-3 9H2"/></svg>
          </div>
          <h3>Key Mechanisms</h3>
          <ul class="check-list">
            <li>Slows gastric emptying, keeping you fuller longer</li>
            <li>Reduces appetite signals in the hypothalamus</li>
            <li>Improves insulin sensitivity and secretion</li>
            <li>Lowers glucagon secretion after meals</li>
            <li>May reduce inflammation markers</li>
            <li>Potential cardiovascular protective effects</li>
          </ul>
        </div>

        <div class="info-card">
          <div class="info-card-icon green">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M12 2L2 7l10 5 10-5-10-5z"/><path d="M2 17l10 5 10-5"/><path d="M2 12l10 5 10-5"/></svg>
          </div>
          <h3>FDA-Approved Uses</h3>
          <ul class="check-list">
            <li>Type 2 diabetes management</li>
            <li>Chronic weight management (BMI &ge;30, or &ge;27 with comorbidity)</li>
            <li>Cardiovascular risk reduction (select medications)</li>
            <li>Obstructive sleep apnea (tirzepatide, 2024)</li>
          </ul>
        </div>
      </div>

      <div class="callout">
        <div class="callout-icon">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><circle cx="12" cy="12" r="10"/><line x1="12" y1="8" x2="12" y2="12"/><line x1="12" y1="16" x2="12.01" y2="16"/></svg>
        </div>
        <div>
          <strong>Important Distinction: GLP-1 vs. GLP-1/GIP Dual Agonists</strong>
          <p>Tirzepatide (Mounjaro/Zepbound) is technically a dual GLP-1/GIP receptor agonist, meaning it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism may contribute to its higher efficacy in weight loss trials. Throughout this guide, we use "GLP-1" as a general category that includes dual agonists for simplicity.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Medications Section -->
  <section class="section section-alt" id="medications">
    <div class="container">
      <div class="section-header">
        <span class="section-label">FDA-Approved Options</span>
        <h2>Current GLP-1 Medications</h2>
        <p class="section-intro">All medications listed below have received FDA approval. Your prescribing clinician will determine which medication and dosage is appropriate based on your individual health profile. Use this as a starting point for informed conversations with your care team.</p>
      </div>

      <div class="med-grid">
        <!-- Semaglutide -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Semaglutide</h3>
              <span class="med-brand">Ozempic (injection) &middot; Rybelsus (oral)</span>
            </div>
            <span class="med-badge diabetes">Type 2 Diabetes</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Weekly subcutaneous injection or daily oral tablet</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>0.25mg &ndash; 2.0mg (injection); 3mg &ndash; 14mg (oral)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2017 (Ozempic); 2019 (Rybelsus)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>SUSTAIN trials: A1C reduction of 1.5&ndash;1.8%; weight loss of 4.5&ndash;6.5 kg</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">CV Benefit</span>
              <span>SELECT trial demonstrated 20% reduction in major cardiovascular events</span>
            </div>
          </div>
        </div>

        <!-- Wegovy -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Semaglutide (higher dose)</h3>
              <span class="med-brand">Wegovy</span>
            </div>
            <span class="med-badge weight">Weight Management</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Weekly subcutaneous injection</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>0.25mg titration up to 2.4mg maintenance</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2021 (chronic weight management); 2024 (CV risk reduction)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>STEP trials: mean weight loss of ~15% of body weight at 68 weeks</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Indication</span>
              <span>BMI &ge;30, or BMI &ge;27 with at least one weight-related comorbidity</span>
            </div>
          </div>
        </div>

        <!-- Tirzepatide -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Tirzepatide</h3>
              <span class="med-brand">Mounjaro (diabetes) &middot; Zepbound (weight)</span>
            </div>
            <span class="med-badge dual">Dual GLP-1/GIP</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Weekly subcutaneous injection</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>2.5mg titration up to 15mg maintenance</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2022 (Mounjaro); 2023 (Zepbound)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>SURMOUNT-1: up to 22.5% body weight reduction at 72 weeks (15mg dose)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Unique Aspect</span>
              <span>Dual receptor mechanism may produce greater metabolic benefits</span>
            </div>
          </div>
        </div>

        <!-- Liraglutide -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Liraglutide</h3>
              <span class="med-brand">Victoza (diabetes) &middot; Saxenda (weight)</span>
            </div>
            <span class="med-badge diabetes">First Generation</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Daily subcutaneous injection</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>0.6mg &ndash; 1.8mg (Victoza); up to 3.0mg (Saxenda)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2010 (Victoza); 2014 (Saxenda)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>SCALE trial: ~8% body weight loss; LEADER trial: CV benefit demonstrated</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Note</span>
              <span>Requires daily injection; newer agents offer weekly dosing with greater efficacy</span>
            </div>
          </div>
        </div>

        <!-- Dulaglutide -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Dulaglutide</h3>
              <span class="med-brand">Trulicity</span>
            </div>
            <span class="med-badge diabetes">Type 2 Diabetes</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Weekly subcutaneous injection</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>0.75mg &ndash; 4.5mg</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2014</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>AWARD trials: A1C reduction ~1.5%; moderate weight loss of 3&ndash;5 kg</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">CV Benefit</span>
              <span>REWIND trial showed reduced cardiovascular events</span>
            </div>
          </div>
        </div>

        <!-- Exenatide -->
        <div class="med-card">
          <div class="med-header">
            <div>
              <h3>Exenatide</h3>
              <span class="med-brand">Byetta (twice daily) &middot; Bydureon (weekly)</span>
            </div>
            <span class="med-badge diabetes">First Approved GLP-1</span>
          </div>
          <div class="med-body">
            <div class="med-detail">
              <span class="med-detail-label">Administration</span>
              <span>Twice-daily or weekly subcutaneous injection</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Dose Range</span>
              <span>5&ndash;10mcg twice daily (Byetta); 2mg weekly (Bydureon)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">FDA Approved</span>
              <span>2005 (Byetta); 2012 (Bydureon)</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Key Trial Data</span>
              <span>Moderate A1C reduction (~1%); modest weight loss of 2&ndash;3 kg</span>
            </div>
            <div class="med-detail">
              <span class="med-detail-label">Note</span>
              <span>The first FDA-approved GLP-1 RA; largely supplanted by newer agents</span>
            </div>
          </div>
        </div>
      </div>

      <div class="callout callout-warning">
        <div class="callout-icon">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>
        </div>
        <div>
          <strong>Compounded GLP-1 Products</strong>
          <p>As of early 2025, the FDA has taken action regarding compounded semaglutide and tirzepatide products. Compounded medications are not FDA-approved, do not undergo the same rigorous testing, and may differ in purity, potency, and sterility. The FDA has issued warnings about adverse events linked to compounded GLP-1 products. This guide covers only FDA-approved medications from licensed manufacturers.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Common Side Effects -->
  <section class="section" id="side-effects">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Side-Effect Playbook</span>
        <h2>Common Side Effects &amp; Management</h2>
        <p class="section-intro">Most side effects occur during dose titration and often diminish over time. Each card below follows a "what to try first" and "when to talk to a clinician" framework. Always consult your clinician about persistent or severe symptoms.</p>
      </div>

      <div class="side-effects-grid">
        <div class="se-card">
          <div class="se-severity mild">Common</div>
          <h4>Nausea</h4>
          <p>The most frequently reported side effect, affecting 15&ndash;44% of users depending on the medication and dose.</p>
          <div class="se-management">
            <strong>What to try first:</strong> Eat smaller meals, avoid high-fat/greasy foods, stay hydrated, follow your titration schedule carefully. Typically improves after 4&ndash;8 weeks.
          </div>
          <div class="se-clinician">
            <strong>Talk to your clinician if:</strong> Nausea persists beyond 8 weeks, prevents you from eating adequately, or is accompanied by vomiting more than once per week.
          </div>
        </div>

        <div class="se-card">
          <div class="se-severity mild">Common</div>
          <h4>Decreased Appetite</h4>
          <p>A therapeutic effect, but can lead to inadequate nutrition if not managed intentionally.</p>
          <div class="se-management">
            <strong>What to try first:</strong> Prioritize protein at every meal (see Nutrition section). Set meal reminders. Track daily protein and calorie intake to ensure adequate nutrition.
          </div>
          <div class="se-clinician">
            <strong>Talk to your clinician if:</strong> You are consistently eating below 1,200 kcal/day, experiencing unintended rapid weight loss, or noticing signs of malnutrition (hair loss, extreme fatigue).
          </div>
        </div>

        <div class="se-card">
          <div class="se-severity mild">Common</div>
          <h4>GI Symptoms</h4>
          <p>Diarrhea, constipation, and abdominal discomfort are reported in 5&ndash;20% of patients.</p>
          <div class="se-management">
            <strong>What to try first:</strong> Increase fiber gradually, stay well-hydrated, consider a fiber supplement for constipation. Ginger tea or peppermint may help with bloating.
          </div>
          <div class="se-clinician">
            <strong>Talk to your clinician if:</strong> Diarrhea persists beyond 2 weeks, you notice blood in stool, or abdominal pain is severe or worsening.
          </div>
        </div>

        <div class="se-card">
          <div class="se-severity moderate">Less Common</div>
          <h4>Injection Site Reactions</h4>
          <p>Redness, swelling, or itching at the injection site in approximately 5&ndash;10% of patients.</p>
          <div class="se-management">
            <strong>Management:</strong> Rotate injection sites between abdomen, thigh, and upper arm. Allow medications to reach room temperature before injecting.
          </div>
        </div>

        <div class="se-card">
          <div class="se-severity moderate">Less Common</div>
          <h4>Fatigue &amp; Dizziness</h4>
          <p>May occur especially during initial titration or if calorie intake drops too low.</p>
          <div class="se-management">
            <strong>Management:</strong> Ensure adequate caloric intake (do not drop below 1,200&ndash;1,500 kcal/day without medical supervision). Stay hydrated. Adjust exercise intensity during titration periods.
          </div>
        </div>

        <div class="se-card">
          <div class="se-severity serious">Rare &mdash; Seek Care</div>
          <h4>Pancreatitis</h4>
          <p>Rare but serious. Symptoms include severe, persistent abdominal pain radiating to the back, often with vomiting.</p>
          <div class="se-management">
            <strong>Action:</strong> Stop the medication and seek emergency medical care immediately. History of pancreatitis is a relative contraindication for GLP-1 RA use.
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Men's Health Section -->
  <section class="section section-alt" id="mens-health">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Male-Specific Considerations</span>
        <h2>GLP-1s &amp; Men's Health</h2>
        <p class="section-intro">Research continues to reveal how GLP-1 receptor agonists interact with male-specific health concerns. Here is what the current evidence shows.</p>
      </div>

      <div class="mens-health-grid">
        <div class="mh-card">
          <h3>Testosterone &amp; Hormonal Health</h3>
          <p>Obesity is strongly associated with lower testosterone levels in men. Excess adipose tissue increases aromatase activity, converting testosterone to estradiol. Studies indicate that significant weight loss from GLP-1 RA therapy can lead to meaningful increases in total and free testosterone levels.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> A 2023 meta-analysis found that men who lost >10% body weight via GLP-1 RA therapy experienced average testosterone increases of 100&ndash;200 ng/dL. The STEP trials showed that this hormonal improvement correlated with improved energy, mood, and sexual function scores.
          </div>
          <div class="mh-note">
            <strong>Practical note:</strong> If you are on testosterone replacement therapy (TRT), discuss with your clinician whether GLP-1 RA-related weight loss may allow dose adjustments to your TRT protocol.
          </div>
        </div>

        <div class="mh-card">
          <h3>Muscle Mass Preservation</h3>
          <p>A primary concern for men on GLP-1 therapy is the loss of lean body mass alongside fat loss. Clinical data from the STEP trials showed that approximately 25&ndash;40% of total weight lost was lean mass&mdash;a ratio that can be improved with intentional strategies.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> Resistance training during GLP-1 therapy has been shown to reduce lean mass loss to 10&ndash;20% of total weight lost. Adequate protein intake (1.2&ndash;1.6 g/kg/day) further supports muscle preservation. The combination of both is considered the standard of care.
          </div>
          <div class="mh-note">
            <strong>Practical note:</strong> See the Exercise and Nutrition sections below for specific protocols designed to preserve muscle during GLP-1 therapy.
          </div>
        </div>

        <div class="mh-card">
          <h3>Cardiovascular Health</h3>
          <p>Heart disease remains the leading cause of death in men. Several GLP-1 receptor agonists have demonstrated cardiovascular benefit beyond weight and glucose management.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> The SELECT trial (semaglutide 2.4mg) showed a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults without diabetes. The LEADER, SUSTAIN-6, and REWIND trials demonstrated similar CV benefits for liraglutide, semaglutide, and dulaglutide respectively in type 2 diabetes populations.
          </div>
        </div>

        <div class="mh-card">
          <h3>Sexual Health &amp; Fertility</h3>
          <p>Weight loss through GLP-1 therapy may improve erectile function and libido through multiple pathways: increased testosterone, improved vascular function, reduced inflammation, and better psychological well-being.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> Studies show improvement in IIEF (International Index of Erectile Function) scores with significant weight loss. Improved insulin sensitivity and reduced visceral adiposity contribute to better endothelial function.
          </div>
          <div class="mh-note">
            <strong>Fertility note:</strong> Current evidence does not suggest that GLP-1 RAs directly impair male fertility. However, if actively trying to conceive, discuss timing with your clinician, as the FDA recommends stopping semaglutide and tirzepatide at least 2 months before planned conception (primarily studied in females).
          </div>
        </div>

        <div class="mh-card">
          <h3>Mental Health &amp; Cognitive Effects</h3>
          <p>The relationship between GLP-1 RAs and mental health is an active area of research. Many men report improved mood, confidence, and energy with weight loss, while a small subset report mood changes.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> Large-scale safety analyses (including FDA and EMA reviews) have not confirmed a causal link between GLP-1 RAs and depression or suicidal ideation. Emerging research suggests potential neuroprotective properties, with ongoing trials studying GLP-1 RAs for Alzheimer's and Parkinson's disease.
          </div>
          <div class="mh-note">
            <strong>Practical note:</strong> If you experience significant mood changes after starting a GLP-1 RA, discuss them with your clinician. Rapid caloric restriction itself can affect mood independent of medication.
          </div>
        </div>

        <div class="mh-card">
          <h3>Sleep Apnea</h3>
          <p>Obstructive sleep apnea (OSA) disproportionately affects men and is strongly correlated with obesity. Weight loss from GLP-1 therapy can significantly improve or resolve OSA.</p>
          <div class="mh-evidence">
            <strong>Evidence:</strong> The SURMOUNT-OSA trial led to FDA approval of tirzepatide (Zepbound) for moderate-to-severe OSA in 2024. Participants experienced significant reductions in AHI (apnea-hypopnea index) scores, with some patients no longer requiring CPAP therapy.
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Nutrition Section -->
  <section class="section" id="nutrition">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Nutrition Guide</span>
        <h2>Protein &amp; Nutrition When Appetite Is Low</h2>
        <p class="section-intro">Reduced appetite is a primary mechanism of GLP-1 medications. Strategic nutrition ensures you lose fat while preserving muscle, energy, and overall health. This is one of the most important guides on the site&mdash;getting nutrition right changes outcomes.</p>
      </div>

      <div class="nutrition-priorities">
        <div class="priority-card">
          <div class="priority-number">1</div>
          <div class="priority-content">
            <h3>Protein First &mdash; At Every Meal</h3>
            <p>Protein is the single most important macronutrient during GLP-1 therapy. It preserves lean muscle mass, supports recovery from exercise, and has the highest thermic effect of any macronutrient.</p>
            <div class="target-box">
              <div class="target">
                <span class="target-label">Daily Target</span>
                <span class="target-value">1.2 &ndash; 1.6 g per kg of body weight</span>
              </div>
              <div class="target">
                <span class="target-label">Per Meal Target</span>
                <span class="target-value">30 &ndash; 50 g of protein per meal</span>
              </div>
              <div class="target">
                <span class="target-label">Example (200 lb male)</span>
                <span class="target-value">109 &ndash; 145 g of protein per day</span>
              </div>
            </div>
            <div class="food-list">
              <strong>Prioritize:</strong> Chicken breast, lean ground turkey, fish (salmon, cod, tuna), eggs/egg whites, Greek yogurt, cottage cheese, lean beef, whey/casein protein supplements.
            </div>
          </div>
        </div>

        <div class="priority-card">
          <div class="priority-number">2</div>
          <div class="priority-content">
            <h3>Don't Under-Eat</h3>
            <p>GLP-1 medications can suppress appetite to the point where caloric intake drops dangerously low. Severe caloric restriction accelerates muscle loss, causes fatigue, impairs immune function, and can stall metabolism.</p>
            <div class="target-box">
              <div class="target">
                <span class="target-label">Minimum Calories</span>
                <span class="target-value">1,500 kcal/day for most men (consult your clinician)</span>
              </div>
              <div class="target">
                <span class="target-label">Recommended Deficit</span>
                <span class="target-value">500 &ndash; 750 kcal/day below maintenance</span>
              </div>
            </div>
            <p><strong>Tip:</strong> If you struggle to eat enough, focus on nutrient-dense, calorie-appropriate foods. Consider protein shakes, smoothies with added nut butter, or Greek yogurt parfaits to meet your targets without needing large volumes of food.</p>
          </div>
        </div>

        <div class="priority-card">
          <div class="priority-number">3</div>
          <div class="priority-content">
            <h3>Micronutrients &amp; Hydration</h3>
            <p>Reduced food intake means reduced micronutrient intake. Proactively address potential deficiencies, especially those common in men on caloric restriction.</p>
            <div class="target-box">
              <div class="target">
                <span class="target-label">Water Intake</span>
                <span class="target-value">Minimum 64 oz/day; more with exercise</span>
              </div>
              <div class="target">
                <span class="target-label">Key Supplements to Discuss</span>
                <span class="target-value">Vitamin D, Magnesium, Omega-3, B-vitamins, Zinc</span>
              </div>
            </div>
            <p><strong>Tip:</strong> Ask your clinician about checking vitamin D, B12, iron, and magnesium levels at baseline and periodically during therapy. Deficiencies in these nutrients can cause fatigue, brain fog, and muscle cramps that may be mistakenly attributed to the medication.</p>
          </div>
        </div>

        <div class="priority-card">
          <div class="priority-number">4</div>
          <div class="priority-content">
            <h3>Meal Timing &amp; Structure</h3>
            <p>When appetite is reduced, structure becomes essential. Plan meals around your injection schedule and daily routine.</p>
            <ul class="check-list">
              <li>Eat protein first at each meal before vegetables and carbohydrates</li>
              <li>Aim for 3 meals and 1&ndash;2 protein-rich snacks daily</li>
              <li>Some men find appetite is lowest 1&ndash;3 days post-injection; front-load nutrition on higher-appetite days</li>
              <li>Avoid large, heavy meals that can worsen GI side effects</li>
              <li>Limit alcohol, especially early in therapy&mdash;many men report heightened sensitivity to alcohol on GLP-1 medications</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="sample-day">
        <h3>Sample Day of Eating (~1,800 kcal, ~140g protein)</h3>
        <div class="meals-grid">
          <div class="meal">
            <span class="meal-label">Breakfast</span>
            <span class="meal-desc">3-egg omelet with spinach and feta, 1 slice whole grain toast</span>
            <span class="meal-macros">~35g protein, 400 kcal</span>
          </div>
          <div class="meal">
            <span class="meal-label">Snack</span>
            <span class="meal-desc">1 cup Greek yogurt (plain, 2%) with berries and 1 tbsp chia seeds</span>
            <span class="meal-macros">~20g protein, 200 kcal</span>
          </div>
          <div class="meal">
            <span class="meal-label">Lunch</span>
            <span class="meal-desc">6 oz grilled chicken breast, mixed greens salad with olive oil dressing, &frac12; cup quinoa</span>
            <span class="meal-macros">~45g protein, 500 kcal</span>
          </div>
          <div class="meal">
            <span class="meal-label">Snack</span>
            <span class="meal-desc">Protein shake (whey protein with water or almond milk)</span>
            <span class="meal-macros">~25g protein, 150 kcal</span>
          </div>
          <div class="meal">
            <span class="meal-label">Dinner</span>
            <span class="meal-desc">5 oz salmon fillet, roasted broccoli and sweet potato</span>
            <span class="meal-macros">~35g protein, 550 kcal</span>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Exercise Section -->
  <section class="section section-alt" id="exercise">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Training Guide</span>
        <h2>Strength Training &amp; Muscle Retention</h2>
        <p class="section-intro">Exercise is not optional during GLP-1 therapy&mdash;it is essential. Resistance training in particular is the most powerful tool for preserving lean mass and ensuring that weight lost is predominantly fat. This guide is built for men focused on health, function, and body composition.</p>
      </div>

      <div class="exercise-pillars">
        <div class="pillar">
          <div class="pillar-header resistance">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6.5 6.5h11M6.5 17.5h11M4 10h2.5v4H4a1 1 0 0 1-1-1v-2a1 1 0 0 1 1-1zM17.5 10H20a1 1 0 0 1 1 1v2a1 1 0 0 1-1 1h-2.5v-4z"/></svg>
            <h3>Resistance Training</h3>
            <span class="pillar-priority">Highest Priority</span>
          </div>
          <div class="pillar-body">
            <p>Resistance training is the most evidence-supported intervention for preserving muscle mass during caloric deficit and GLP-1 therapy. It should be the foundation of your exercise program.</p>
            <div class="exercise-rx">
              <h4>Recommended Protocol</h4>
              <ul>
                <li><strong>Frequency:</strong> 3&ndash;4 sessions per week</li>
                <li><strong>Focus:</strong> Compound movements (squat, deadlift, bench press, overhead press, rows, pull-ups)</li>
                <li><strong>Volume:</strong> 3&ndash;4 sets of 6&ndash;12 reps per exercise</li>
                <li><strong>Progression:</strong> Progressive overload&mdash;gradually increase weight, reps, or sets over time</li>
                <li><strong>Recovery:</strong> 48 hours between training the same muscle group</li>
              </ul>
            </div>
            <div class="exercise-note">
              <strong>New to lifting?</strong> Start with bodyweight exercises or machines, learn proper form (consider a few sessions with a certified personal trainer), and progress gradually. Muscle preservation benefits begin even with moderate resistance training.
            </div>
          </div>
        </div>

        <div class="pillar">
          <div class="pillar-header cardio">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M20.84 4.61a5.5 5.5 0 0 0-7.78 0L12 5.67l-1.06-1.06a5.5 5.5 0 0 0-7.78 7.78l1.06 1.06L12 21.23l7.78-7.78 1.06-1.06a5.5 5.5 0 0 0 0-7.78z"/></svg>
            <h3>Cardiovascular Training</h3>
            <span class="pillar-priority">Important for Heart Health</span>
          </div>
          <div class="pillar-body">
            <p>Cardiovascular exercise supports heart health, improves insulin sensitivity, and boosts mood. Balance cardio with resistance training&mdash;excessive cardio without adequate protein can accelerate muscle loss.</p>
            <div class="exercise-rx">
              <h4>Recommended Protocol</h4>
              <ul>
                <li><strong>Frequency:</strong> 2&ndash;3 sessions per week (in addition to resistance training)</li>
                <li><strong>Type:</strong> Walking, cycling, swimming, rowing, or elliptical</li>
                <li><strong>Duration:</strong> 20&ndash;40 minutes per session</li>
                <li><strong>Intensity:</strong> Moderate (can hold a conversation but slightly breathless)</li>
                <li><strong>Goal:</strong> 150+ minutes of moderate cardio per week (AHA guideline)</li>
              </ul>
            </div>
            <div class="exercise-note">
              <strong>Zone 2 training</strong> (steady-state, conversational pace) is particularly effective for fat oxidation and cardiovascular adaptation. It also supports recovery from resistance training sessions.
            </div>
          </div>
        </div>

        <div class="pillar">
          <div class="pillar-header flexibility">
            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M4 15s1-1 4-1 5 2 8 2 4-1 4-1V3s-1 1-4 1-5-2-8-2-4 1-4 1z"/><line x1="4" y1="22" x2="4" y2="15"/></svg>
            <h3>Mobility &amp; Recovery</h3>
            <span class="pillar-priority">Supports Longevity</span>
          </div>
          <div class="pillar-body">
            <p>As you lose weight, your body mechanics change. Mobility work prevents injury, supports joint health, and improves performance in both resistance and cardio training.</p>
            <div class="exercise-rx">
              <h4>Recommended Protocol</h4>
              <ul>
                <li><strong>Dynamic stretching:</strong> 5&ndash;10 minutes before every workout</li>
                <li><strong>Static stretching:</strong> 10+ minutes after workouts, focusing on tight areas</li>
                <li><strong>Dedicated sessions:</strong> 1&ndash;2 yoga or mobility sessions per week</li>
                <li><strong>Sleep:</strong> 7&ndash;9 hours per night (critical for muscle recovery and hormonal health)</li>
                <li><strong>Step count:</strong> Aim for 7,000&ndash;10,000 steps daily as baseline activity</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <div class="callout">
        <div class="callout-icon">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><circle cx="12" cy="12" r="10"/><line x1="12" y1="8" x2="12" y2="12"/><line x1="12" y1="16" x2="12.01" y2="16"/></svg>
        </div>
        <div>
          <strong>Exercise During Dose Titration</strong>
          <p>During dose increases, you may experience increased nausea or fatigue. It is acceptable to temporarily reduce exercise intensity (but not frequency) during titration periods. Maintain your training schedule with lighter weights or shorter sessions rather than skipping workouts entirely. Resume normal intensity once side effects stabilize.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- FAQ Section -->
  <section class="section" id="faq">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Your Questions Answered</span>
        <h2>Frequently Asked Questions</h2>
      </div>

      <div class="faq-list">
        <details class="faq-item">
          <summary>What happens when I stop taking a GLP-1 medication?</summary>
          <div class="faq-answer">
            <p>Clinical evidence consistently shows that weight regain occurs after discontinuation of GLP-1 therapy if lifestyle modifications are not maintained. The STEP 1 extension trial found that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide.</p>
            <p>This is not a personal failure&mdash;it reflects the biological reality that obesity is a chronic condition, similar to hypertension or type 2 diabetes. Some patients may require long-term therapy, while others may be able to taper or discontinue with sufficient lifestyle changes. Discuss a long-term plan with your clinician before making changes to your medication.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>Will GLP-1 medications affect my testosterone levels?</summary>
          <div class="faq-answer">
            <p>In most cases, the effect is positive. Obesity-related hypogonadism is common in men, and the weight loss achieved through GLP-1 therapy frequently leads to improvements in total and free testosterone. Some men who were borderline low at baseline have seen their levels normalize with significant weight loss.</p>
            <p>However, if you are currently on testosterone replacement therapy (TRT), work with your clinician to monitor levels and adjust your TRT protocol as your body composition changes.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>Can I drink alcohol while on a GLP-1 medication?</summary>
          <div class="faq-answer">
            <p>Alcohol is not strictly contraindicated, but many men report increased sensitivity to alcohol while on GLP-1 therapy. This may be due to delayed gastric emptying, reduced food intake, or altered metabolism. Alcohol also provides empty calories that work against your goals and can worsen GI side effects.</p>
            <p><strong>Practical guidance:</strong> If you choose to drink, start slowly to gauge your tolerance, eat protein-rich food beforehand, stay hydrated, and limit intake. Be aware of hypoglycemia risk if you are also on diabetes medications.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>How long does it take to see results?</summary>
          <div class="faq-answer">
            <p>Most men notice appetite reduction within the first 1&ndash;2 weeks. Measurable weight loss typically begins within 4&ndash;6 weeks as doses are titrated upward. The full effect of the maintenance dose is usually observed after 3&ndash;6 months of consistent use.</p>
            <p>Clinical trial data (STEP and SURMOUNT programs) showed that weight loss continued gradually for 60&ndash;72 weeks before plateauing. Individual results vary based on starting weight, dose, adherence, diet, and exercise habits.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>Is "GLP-1 face" (facial volume loss) a real concern?</summary>
          <div class="faq-answer">
            <p>Facial volume loss can occur with any significant weight loss, not specifically from GLP-1 medications. The subcutaneous fat in the face decreases along with overall body fat, which can lead to a more aged or gaunt appearance in some individuals.</p>
            <p>Strategies to minimize this include: maintaining adequate protein intake, staying hydrated, losing weight at a moderate pace (1&ndash;2 lbs/week), and using sunscreen to support skin elasticity. Some men may choose to consult a dermatologist about skin care during significant weight loss.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>Do I need to take GLP-1 medications forever?</summary>
          <div class="faq-answer">
            <p>Current evidence supports viewing GLP-1 RAs similarly to other chronic disease medications. While some patients can successfully discontinue with robust lifestyle modifications, the majority of clinical data suggests that long-term use provides the most sustained benefit for weight management and metabolic health.</p>
            <p>This is a conversation to have with your clinician based on your individual goals, health status, and response to treatment. Some clinicians are exploring dose reduction strategies (rather than full discontinuation) for maintenance, though this is not yet standardized in guidelines.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>Are there any interactions with supplements or other medications I should know about?</summary>
          <div class="faq-answer">
            <p>GLP-1 RAs can slow the absorption of oral medications due to delayed gastric emptying. This is particularly relevant for medications with narrow therapeutic windows (e.g., warfarin, levothyroxine, oral contraceptives). Always inform your prescribing clinician of all medications and supplements you take.</p>
            <p>Common supplements like creatine, whey protein, vitamin D, and fish oil are generally considered safe to take alongside GLP-1 therapy, but always confirm with your clinician.</p>
          </div>
        </details>

        <details class="faq-item">
          <summary>What is the cost, and does insurance cover GLP-1 medications?</summary>
          <div class="faq-answer">
            <p>Without insurance, GLP-1 medications can cost $800&ndash;$1,500+ per month. Coverage varies significantly by insurance plan, indication (diabetes vs. weight loss), and specific medication. Many insurers cover GLP-1 RAs for type 2 diabetes but not for weight management alone.</p>
            <p>Check with your insurer, explore manufacturer savings programs (e.g., Eli Lilly and Novo Nordisk offer patient assistance programs), and discuss formulary alternatives with your clinician if cost is a barrier. The legislative and insurance landscape for obesity medications is evolving.</p>
          </div>
        </details>
      </div>
    </div>
  </section>

  <!-- Weekly Digest Signup -->
  <section class="section digest-section" id="weekly-digest">
    <div class="container">
      <div class="digest-content">
        <div class="digest-text">
          <span class="section-label">Stay Current</span>
          <h2>Get the Weekly Digest</h2>
          <p>A short, curated update on GLP-1 research and practical guidance&mdash;written for men focused on health, function, and body composition. Each item includes an evidence grade so you know how much weight to give it.</p>
          <div class="evidence-grades-legend">
            <div class="eg-item">
              <span class="eg-badge a">A</span>
              <span>Guidelines, large RCTs, high-quality meta-analyses</span>
            </div>
            <div class="eg-item">
              <span class="eg-badge b">B</span>
              <span>Smaller RCTs, strong observational studies, coherent evidence base</span>
            </div>
            <div class="eg-item">
              <span class="eg-badge c">C</span>
              <span>Preprints, early mechanistic findings&mdash;worth knowing, but provisional</span>
            </div>
          </div>
        </div>
        <div class="digest-form">
          <form class="subscribe-form" onsubmit="event.preventDefault(); this.querySelector('.subscribe-btn').textContent='Subscribed!'; this.querySelector('.subscribe-btn').disabled=true;">
            <label for="digest-email">Email address</label>
            <div class="subscribe-input-group">
              <input type="email" id="digest-email" placeholder="you@example.com" required>
              <button type="submit" class="btn btn-primary subscribe-btn">Subscribe</button>
            </div>
            <p class="subscribe-note">No spam. Unsubscribe anytime. We never share your email.</p>
          </form>
        </div>
      </div>
    </div>
  </section>

  <!-- Resources Section -->
  <section class="section section-alt" id="resources">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Trusted Sources</span>
        <h2>Further Reading &amp; Resources</h2>
        <p class="section-intro">All information on this site is based on peer-reviewed research, FDA labeling, and established clinical guidelines. We prioritize primary sources and clearly label the certainty of evidence.</p>
      </div>

      <div class="resources-grid">
        <div class="resource-card">
          <h4>Clinical Guidelines</h4>
          <ul class="resource-list">
            <li>
              <strong>American Diabetes Association (ADA)</strong>
              <span>Standards of Care in Diabetes &mdash; updated annually</span>
            </li>
            <li>
              <strong>American Heart Association (AHA)</strong>
              <span>Guidelines on cardiovascular risk management and obesity</span>
            </li>
            <li>
              <strong>The Obesity Society / AACE</strong>
              <span>Clinical practice guidelines for obesity treatment</span>
            </li>
            <li>
              <strong>Endocrine Society</strong>
              <span>Guidelines on testosterone deficiency and metabolic health in men</span>
            </li>
          </ul>
        </div>

        <div class="resource-card">
          <h4>Key Clinical Trials</h4>
          <ul class="resource-list">
            <li>
              <strong>STEP Program</strong>
              <span>Semaglutide 2.4mg trials for chronic weight management</span>
            </li>
            <li>
              <strong>SURMOUNT Program</strong>
              <span>Tirzepatide trials for obesity and related conditions</span>
            </li>
            <li>
              <strong>SELECT Trial</strong>
              <span>Semaglutide cardiovascular outcomes in overweight/obese adults</span>
            </li>
            <li>
              <strong>SUSTAIN / PIONEER Programs</strong>
              <span>Semaglutide for type 2 diabetes (injection and oral)</span>
            </li>
            <li>
              <strong>LEADER / REWIND Trials</strong>
              <span>CV outcomes for liraglutide and dulaglutide</span>
            </li>
          </ul>
        </div>

        <div class="resource-card">
          <h4>Government &amp; Regulatory</h4>
          <ul class="resource-list">
            <li>
              <strong>FDA Drug Safety Communications</strong>
              <span>Alerts and updates on GLP-1 RA safety</span>
            </li>
            <li>
              <strong>FDA/EMA Prescribing Information</strong>
              <span>Official labels for all approved GLP-1 medications</span>
            </li>
            <li>
              <strong>ClinicalTrials.gov</strong>
              <span>Registry of ongoing and completed GLP-1 clinical trials</span>
            </li>
            <li>
              <strong>NIH / NIDDK</strong>
              <span>National Institute of Diabetes and Digestive and Kidney Diseases</span>
            </li>
          </ul>
        </div>

        <div class="resource-card">
          <h4>Nutrition &amp; Exercise</h4>
          <ul class="resource-list">
            <li>
              <strong>ISSN Position Stands</strong>
              <span>International Society of Sports Nutrition on protein, supplements</span>
            </li>
            <li>
              <strong>ACSM Exercise Guidelines</strong>
              <span>American College of Sports Medicine resistance training guidelines</span>
            </li>
            <li>
              <strong>USDA Dietary Guidelines</strong>
              <span>Federal nutrition recommendations, updated every 5 years</span>
            </li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <!-- Editorial Standards -->
  <section class="section" id="editorial-standards">
    <div class="container">
      <div class="section-header">
        <span class="section-label">Transparency</span>
        <h2>Editorial Standards</h2>
        <p class="section-intro">WeBrovy.com is built on three principles: accuracy, transparency, and usefulness.</p>
      </div>

      <div class="standards-grid">
        <div class="standard-card">
          <h3>1. Sources &amp; Evidence</h3>
          <p>We prioritize sources in this order:</p>
          <ol class="numbered-list">
            <li>Clinical guidelines and consensus statements</li>
            <li>FDA/EMA prescribing information and safety updates</li>
            <li>Peer-reviewed randomized controlled trials</li>
            <li>High-quality observational studies</li>
            <li>Mechanistic studies and expert commentary (clearly labeled as lower certainty)</li>
          </ol>
          <p>When evidence is limited or evolving, we say so explicitly.</p>
        </div>

        <div class="standard-card">
          <h3>2. Evidence Grades</h3>
          <p>Used throughout the Weekly Digest and guides to signal confidence level:</p>
          <div class="evidence-grades-detail">
            <div class="egd-row">
              <span class="eg-badge a">A</span>
              <div>
                <strong>Grade A</strong>
                <span>Guidelines, large RCTs, high-quality meta-analyses</span>
              </div>
            </div>
            <div class="egd-row">
              <span class="eg-badge b">B</span>
              <div>
                <strong>Grade B</strong>
                <span>Smaller RCTs, strong observational studies, coherent evidence base</span>
              </div>
            </div>
            <div class="egd-row">
              <span class="eg-badge c">C</span>
              <div>
                <strong>Grade C</strong>
                <span>Preprints, early mechanistic findings, low-quality data, opinion pieces. May still be worth knowing&mdash;but should be treated as provisional.</span>
              </div>
            </div>
          </div>
        </div>

        <div class="standard-card">
          <h3>3. Medical Review &amp; Authorship</h3>
          <p>Content is written in plain language with citations. If a medical reviewer is involved, articles will state "Reviewed by&hellip;" with credentials. If not, we will clearly state that content is not medically reviewed and encourage clinician discussion.</p>
        </div>

        <div class="standard-card">
          <h3>4. Updates &amp; Corrections</h3>
          <p>We aim to update evergreen guides at least every 6&ndash;12 months, or earlier when major evidence, guidance, or safety information changes.</p>
          <p>If you believe something on WeBrovy.com is incorrect, unclear, or out of date, please contact us at <strong>contact@webrovy.com</strong> with the page URL, the specific section in question, and any supporting sources. If a correction is needed, we update the page and note the change (e.g., "Updated on [date]: corrected&hellip;").</p>
        </div>

        <div class="standard-card">
          <h3>5. Independence &amp; Funding</h3>
          <p>WeBrovy.com is currently <strong>self-funded</strong>. If we add advertising or sponsorship in the future, our standards will be:</p>
          <ul class="check-list">
            <li>Clear labeling ("Advertisement," "Sponsored")</li>
            <li>No editorial control by sponsors (no topic selection, no copy approval)</li>
            <li>Category restrictions to avoid misleading or unsafe products</li>
            <li>Disclosure of any affiliate relationships</li>
          </ul>
          <p class="standards-reject"><strong>We do not accept</strong> advertising or sponsorship that promotes unapproved or illegally marketed medications, misleading "miracle" weight-loss claims, or products that conflict with our evidence standards.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Disclaimer -->
  <section class="disclaimer-section">
    <div class="container">
      <div class="disclaimer">
        <h3>Medical Disclaimer</h3>
        <p>The information on WeBrovy.com is for <strong>educational purposes only</strong> and is not medical advice. It does not replace care from a qualified healthcare professional.</p>
        <p>Medication decisions and side-effect management should be made with a clinician who knows your medical history. If you have urgent symptoms or concerns, seek medical attention promptly.</p>
        <p>WeBrovy.com is currently self-funded. No content is sponsored or influenced by industry funding.</p>
      </div>
    </div>
  </section>

  <!-- Footer -->
  <footer class="footer">
    <div class="container">
      <div class="footer-content">
        <div class="footer-brand">
          <span class="footer-logo">We<em>Brovy</em><small>.com</small></span>
          <p>Evidence-based guidance for men using GLP-1 medications for weight management.</p>
        </div>
        <div class="footer-links">
          <div class="footer-col">
            <h4>Guides</h4>
            <a href="#what-are-glp1s">GLP-1 Basics</a>
            <a href="#medications">Medications</a>
            <a href="#side-effects">Side-Effect Playbook</a>
            <a href="#nutrition">Nutrition</a>
            <a href="#exercise">Training</a>
          </div>
          <div class="footer-col">
            <h4>For Men</h4>
            <a href="#start-here">Start Here</a>
            <a href="#mens-health">Men's Health</a>
            <a href="#faq">FAQ</a>
            <a href="#weekly-digest">Weekly Digest</a>
          </div>
          <div class="footer-col">
            <h4>Trust</h4>
            <a href="#editorial-standards">Editorial Standards</a>
            <a href="#our-approach">Our Approach</a>
            <a href="#resources">Sources</a>
          </div>
        </div>
      </div>
      <div class="footer-bottom">
        <p>The information on WeBrovy.com is for educational purposes only and is not medical advice. It does not replace care from a qualified healthcare professional.</p>
      </div>
    </div>
  </footer>

  <script src="script.js"></script>
</body>
</html>
